U.S. Healthcare Services Stock News

American Eagle Outfitters recently reported fourth-quarter and full-year 2025 results, with sales rising to US$1,760.83 million for the quarter and US$5,496.81 million for the year, while net income and earnings per share declined; the company also declared a US$0.125 per-share quarterly dividend payable on April 24, 2026, and continued its buyback program, repurchasing 1,000,000 shares for US$25 million. Management paired this performance with guidance calling for high single-digit...

In recent months, Consolidated Edison has reported updated guidance, capital and financing plans, and seen analysts lift earnings estimates while maintaining a generally cautious stance on the stock. At the same time, the utility has faced scrutiny over prolonged winter power outages and reimbursement disputes, underscoring the operational and regulatory challenges that sit alongside its improving earnings outlook. We’ll now examine how this combination of a brighter earnings outlook and...

CenterPoint Energy (CNP) is back in focus after fourth quarter 2025 earnings matched expectations, the company reaffirmed its 2026 non GAAP earnings guidance, detailed new grid projects, and announced a 9% dividend increase. See our latest analysis for CenterPoint Energy. Recent earnings, grid investment plans and the 9% dividend increase have come alongside firm share price momentum, with a 30 day share price return of 8.89% and a 1 year total shareholder return of 29.59% that extends to...

If you are wondering whether Corvus Pharmaceuticals' recent share price puts it at a bargain or a stretched level, you are not alone. This article is here to unpack what that current price might mean for value focused investors. The stock has been volatile, with a 7 day return of an 11.7% decline and a 30 day return of a 22.8% decline, set against a year to date return of 115.8% and a 1 year return of 271.6%, plus an increase of more than 7x over 3 years and 381.6% over 5 years. Recent...

Revolve Group, Inc. recently launched Revolve Los Angeles, its first namesake fashion house inspired by its hometown, offering couture-influenced womenswear priced between US$200 and US$3,500 in sizes XXS to XL, available exclusively on Revolve and FWRD. This move expands Revolve’s in-house brand portfolio into higher-end, craftsmanship-focused apparel, signalling a push to deepen brand identity and capture more luxury-oriented spending. We’ll now explore how this higher-end Revolve Los...

In recent days, Essex Property Trust’s fourth-quarter 2025 results came in below expectations while the company’s board approved a 0.8% annual dividend increase, marking its 32nd consecutive year of dividend growth. At the same time, a mix of cautious analyst commentary and industry concerns about below pre-COVID multifamily occupancy levels has sharpened investor focus on how Essex balances income stability with near-term operational challenges. Next, we’ll examine how Essex’s earnings...

Why Celcuity (CELC) is Drawing Fresh Attention Celcuity (CELC) has come into focus after recent share price moves and its role as a clinical-stage biotechnology company working on targeted therapies for solid tumors, including advanced breast and prostate cancers. See our latest analysis for Celcuity. The current US$115.0 share price comes after a 6.2% 7 day share price return and an 11.9% 90 day share price return. The 1 year total shareholder return is very large, hinting that recent moves...

Why Denali’s recent earnings and shelf registration matter for shareholders Denali Therapeutics (DNLI) has drawn fresh attention after reporting a wider fourth quarter and full year 2025 loss alongside a new US$200.7 million shelf registration for common stock, raising questions about dilution and funding plans. For the fourth quarter, Denali reported a net loss of US$128.55 million, with basic and diluted loss per share from continuing operations of US$0.73, compared with US$0.67 a year...

In early March 2026, Incyte received European Commission approval for Zynyz (retifanlimab) plus carboplatin and paclitaxel as first-line treatment for adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal, based on Phase 3 POD1UM-303 data showing improved progression-free survival versus chemotherapy alone. This second European indication for Zynyz strengthens Incyte’s immuno-oncology portfolio in a rare cancer setting, underpinned by...

Why Bob's Discount Furniture Is On Investors' Radar Bob's Discount Furniture (BOBS) has drawn attention after a sharp 5.5% decline in the latest session, extending a roughly 18% slide over the past week. At the same time, the share price shows a small gain over the past month and a modest positive return so far this year, giving investors mixed signals on short term sentiment. See our latest analysis for Bob's Discount Furniture. The recent 1 day share price return of a 5.46% decline and 7...

Avnet (AVT) has been drawing attention after recent share price moves, with the stock showing mixed returns over the past week and month while remaining higher over the past 3 months and year. See our latest analysis for Avnet. That pullback, with a 1 month share price return of 9.86% decline and a 1 week share price return of 7.59% decline, comes after a stronger run that leaves Avnet with a 1 year total shareholder return of 24.26% and 3 year total shareholder return of 53.29%. This...

Earnings milestone and buyback completion put REX American Resources in focus REX American Resources (REX) extended its streak to 21 consecutive profitable quarters with stronger-than-expected earnings, while a completed multi-year buyback that retired about 3.6 million shares supported earnings per share. See our latest analysis for REX American Resources. At a share price of $37.38, REX American Resources has seen steady positive momentum, with a 90 day share price return of 14.7% and a 1...

Earnings and corporate actions draw fresh attention to DiamondRock Hospitality DiamondRock Hospitality (DRH) is back on investor radars after its latest quarterly update, which combined a move from quarterly loss to profit, a higher dividend, a completed buyback, and upcoming board changes. See our latest analysis for DiamondRock Hospitality. At a share price of $9.60, DiamondRock Hospitality has seen a 9.34% 90 day share price return and a 20.40% 1 year total shareholder return. This...

Why DraftKings' Super App Plans Matter for DKNG Holders DraftKings (DKNG) has put its planned Super App front and center, aiming to fold Sportsbook, Casino, Lottery and Prediction products into one platform, deepen its ESPN-linked features, and simplify the user experience. See our latest analysis for DraftKings. Despite the Super App announcement, account linking with ESPN, new market entries like Arkansas and Puerto Rico, and mixed legal headlines, DraftKings’ recent momentum has been weak,...

In early March 2026, regional bank stocks including Citizens Financial Group came under pressure after Western Alliance Bancorporation disclosed a US$126.40 million loan write-off tied to a default in the opaque private credit market. At the same time, Citizens continued to push its "Reimagine the Bank" digital transformation and agreed to acquire most assets of Matrix Capital Markets Group, broadening its advisory capabilities in the downstream energy and convenience retail sector. Next,...

Full year 2025 earnings reset the conversation Civitas Resources (CIVI) recently reported full year 2025 results, with revenue of US$4,393 million and net income of US$561 million, both lower than the prior year, putting the stock back under closer investor review. See our latest analysis for Civitas Resources. At a share price of US$27.38, Civitas Resources has seen a 5.0% decline in its 90 day share price return and a 43.4% drop in its 1 year total shareholder return. This suggests momentum...

Q4 earnings and capital moves put MGIC Investment (MTG) in the spotlight MGIC Investment (MTG) drew investor attention after its recent earnings update, which paired flat year over year revenue and an earnings figure in line with expectations, along with a modest post report share price drop. See our latest analysis for MGIC Investment. At a share price of US$26.52, MGIC Investment has seen its short term share price momentum soften, with a year to date share price return of a 9.02% decline...

Why Teradata (TDC) is on investors’ radar today Teradata (TDC) has drawn fresh attention as investors reassess its share performance and fundamentals, with the stock recently closing at US$28.02 after mixed returns over the past year and past 3 months. See our latest analysis for Teradata. Recent trading has been choppy, with a 1 day share price return of a 3.25% decline and a 7 day share price return of a 7.86% decline. However, the 1 year total shareholder return of 24.42% hints that longer...

In late February 2026, Flywire reported fourth-quarter 2025 sales of US$157.54 million and net income of US$0.033 million, alongside full-year 2025 sales of US$623.03 million and net income of US$13.5 million, issued 2026 growth guidance, filed a US$77.86 million ESOP-related shelf registration, and reshaped its technology leadership. The appointment of seasoned payments technologist Patrick Blanc as Chief Technology Officer, coupled with Flywire’s AI-first engineering push and Student...

The Morning Bull - US Market Morning Update Monday, Mar, 9 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 1.3% and Nasdaq 100 futures off roughly 1.5%, as investors react to a jump in borrowing costs and energy prices. The US 10 year Treasury yield is around 4.22%, meaning mortgages, car loans, and corporate borrowing can all stay more expensive for longer, while oil above US$100 keeps pressure on fuel and transport costs. With Middle East...

Timken stock at a glance Timken (TKR) has attracted fresh attention after recent share price moves, with the stock showing mixed short term returns while still posting gains over the past 3 years and 5 years. See our latest analysis for Timken. The recent pullback, including a 9.37% 7 day share price decline and 6.00% 30 day share price decline from around US$99.68, sits against a stronger backdrop, with a 19.87% 90 day share price return and 35.62% 1 year total shareholder return suggesting...

Nextensa, in partnership with Promobe through their Grossfeld joint venture, recently announced that Citi has signed a long-term lease for upper-floor office space in The Rock, a new 9,492 m² landmark building in Luxembourg’s Cloche d’Or district scheduled for mid-2027 delivery. Citi’s move to a high-visibility headquarters location in a rapidly developing financial hub underscores Luxembourg’s importance within its international network and the city’s growing role in European financial...

National Health Investors (NHI) recently reported fourth quarter and full year 2025 results, with higher sales and revenue and softer quarterly earnings, a combination that provides a detailed snapshot of current margin pressures. See our latest analysis for National Health Investors. The mixed fourth quarter earnings and board changes arrived after a period of steadily improving performance, with the latest share price at $84.62, a 90 day share price return of 7.98% and a 1 year total...

Why AppFolio’s latest guidance is attracting fresh attention AppFolio (APPF) is drawing investor focus after management outlined 2026 guidance that pairs revenue of about US$1.1b with an adjusted operating margin near 26.5%, highlighting the impact of higher value, paid services. See our latest analysis for AppFolio. The shares, recently at US$191.17, have rebounded with a 7 day share price return of 5.85% and a 30 day share price return of 6.37%. The 90 day share price return of 18.15% and...